CD8B and cancer: The gene markers of CD8 + T cells, including CD8A and CD8B, major cancer cell killers [30], were also moderately correlated with LAG3. Accordingly, CD8A and CD8B, enhanced by ICOS, alter the tumor immune system, eventually contributing to a better prognosis in patients with MPM.